Detailed Information
Cited 0 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Nanoparticle-Based Chimeric Antigen Receptor Therapy for Cancer Immunotherapy
- Authors
- Shin, S.; Lee, P.; Han, J.; Kim, S.-N.; Lim, J.; Park, D.-H.; Paik, Tae Jong; Min, Junhong; Park, C.G.; Park, W.
- Issue Date
- Jun-2023
- Publisher
- Korean Tissue Engineering and Regenerative Medicine Society
- Keywords
- Cancer immunotherapy; Chimeric antigen receptor (CAR); Genetic engineering; Immune cell reprograming; Nanoparticle
- Citation
- Tissue Engineering and Regenerative Medicine, v.20, no.3, pp 371 - 387
- Pages
- 17
- Journal Title
- Tissue Engineering and Regenerative Medicine
- Volume
- 20
- Number
- 3
- Start Page
- 371
- End Page
- 387
- ISSN
- 1738-2696
2212-5469
- Abstract
- Adoptive cell therapy with chimeric antigen receptor (CAR)-engineered T cells (CAR-Ts) has emerged as an innovative immunotherapy for hematological cancer treatment. However, the limited effect on solid tumors, complex processes, and excessive manufacturing costs remain as limitations of CAR-T therapy. Nanotechnology provides an alternative to the conventional CAR-T therapy. Owing to their unique physicochemical properties, nanoparticles can not only serve as a delivery platform for drugs but also target specific cells. Nanoparticle-based CAR therapy can be applied not only to T cells but also to CAR-natural killer and CAR-macrophage, compensating for some of their limitations. This review focuses on the introduction of nanoparticle-based advanced CAR immune cell therapy and future perspectives on immune cell reprogramming. © 2023, Korean Tissue Engineering and Regenerative Medicine Society.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of ICT Engineering > School of Integrative Engineering > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.